50 results on '"Zachariou, Anna"'
Search Results
2. Photochemically Engineered Large‐Area Arsenic Sulfide Micro‐Gratings for Hybrid Diffractive–Refractive Infrared Platforms
3. Photochemically Engineered Large‐Area Arsenic Sulfide Micro‐Gratings for Hybrid Diffractive–Refractive Infrared Platforms
4. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer
5. Abstract CT093: Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
6. Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
7. Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
8. A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
9. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
10. Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787)
11. Abstract CT120: Results of the glioblastoma multiforme (GBM) cohort of phase 1 trial Ice-CAP (NCT03673787): Preliminary evidence of antitumour activity of Ipatasertib (Ipa) and Atezolizumab (A) in patients (pts) with PTEN loss
12. Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth
13. Abstract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors
14. Abstract CT140: Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation study of Ipatasertib (Ipa) in combination with atezolizumab (A) in patients (pts) with advanced solid tumors (Ice-CAP)
15. The CHD8 overgrowth syndrome: A detailed evaluation of an emerging overgrowth phenotype in 27 patients
16. Null variants and deletions in BRWD3 cause an X‐linked syndrome of mild–moderate intellectual disability, macrocephaly, and obesity: A series of 17 patients
17. The phenotype of Sotos syndrome in adulthood: A review of 44 individuals
18. HIST1H1E heterozygous protein‐truncating variants cause a recognizable syndrome with intellectual disability and distinctive facial gestalt: A study to clarify the HIST1H1E syndrome phenotype in 30 individuals
19. Identification of new Wilms tumour predisposition genes: an exome sequencing study
20. Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation
21. Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma
22. Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability
23. Null variants and deletions in BRWD3cause an X‐linked syndrome of mild–moderate intellectual disability, macrocephaly, and obesity: A series of 17 patients
24. The CHD8overgrowth syndrome: A detailed evaluation of an emerging overgrowth phenotype in 27 patients
25. EED and EZH2 constitutive variants: A study to expand the Cohen‐Gibson syndrome phenotype and contrast it with Weaver syndrome.
26. Photothermally-realized chalcogenide bulk GRIN media.
27. Erratum: Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor
28. Mutations in the transcriptional repressor REST predispose to Wilms tumor
29. Creation of Three-Dimensional Gradient Refractive Index Profiles in Bulk Ge-As-Pb-Se Glasses
30. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour
31. Erratum: A genome-wide association study identifies susceptibility loci for Wilms tumor
32. Erratum: A genome-wide association study identifies susceptibility loci for Wilms tumor
33. A genome-wide association study identifies susceptibility loci for Wilms tumor
34. The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs
35. IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms
36. Degradation of DIAP1 by the N-end rule pathway is essential for regulating apoptosis
37. Jafrac2 is an IAP antagonist that promotes cell death by liberating Dronc from DIAP1
38. The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis
39. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.
40. IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms.
41. Corrigendum: Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth.
42. Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor
43. Corrigendum: Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability.
44. A genome-wide association study identifies susceptibility loci for Wilms tumor.
45. A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
46. Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma
47. Correction: Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.
48. The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants.
49. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.
50. IAP-antagonists exhibit non-redundant modes of action through differential DIAP1 binding.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.